| ID Source | ID |
|---|---|
| PubMed CID | 76960246 |
| MeSH ID | M0060902 |
| Synonym |
|---|
| teferrol |
| ferrum hausmann |
| ferrummate |
| 53858-86-9 |
| amylofer |
| maltofer |
| unii-um5219h89v |
| ferinject |
| ferripel-3 |
| um5219h89v , |
| ferripel 3 |
| ferromaltose |
| Q27291136 |
| iron(3+);(2r,3s,4r,5r)-2,3,4,5-tetrahydroxy-6-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal;trihydroxide |
| Excerpt | Reference | Relevance |
|---|---|---|
| " During the maintenance phase (period of epoetin therapy after correction of iron deficiency), the use of low-dose intravenous iron supplementation (10 to 20 mg per haemodialysis treatment or 100 mg every second week) avoids iron overtreatment and minimises potential adverse effects." | ( Safety aspects of parenteral iron in patients with end-stage renal disease. Hörl, WH; Sunder-Plassmann, G, 1997) | 0.3 |
| "Treatment of iron deficiency anaemia with conventional oral preparations is handicapped by unpredictable haematological response in addition to potential for irritating gastrointestinal adverse events." | ( Evaluation of efficacy and safety of iron polymaltose complex and folic acid (Mumfer) vs iron formulation (ferrous fumarate) in female patients with anaemia. Adsul, BB; Desai, A; Gandewar, K; Korde, KM; Reddy, PS, 2001) | 0.31 |
| " This is usually associated with a lower incidence of adverse events related to the upper gastro intestinal tract." | ( Safety and efficacy of iron(III)-hydroxide polymaltose complex / a review of over 25 years experience. Geisser, P, 2007) | 0.34 |
| " Infusion-related adverse events (AE) and delayed AE over the ensuing 5 days were also prospectively documented and graded as mild, moderate or severe." | ( A rapid infusion protocol is safe for total dose iron polymaltose: time for change. Friedman, A; Garg, M; Gibson, PR; Lau, A; Lau, D; Morrison, G, 2011) | 0.37 |
| " Adverse events were significantly less frequent in the iron(III) polymaltose group, occurring in 12/41 (29." | ( Efficacy and safety of oral iron(III) polymaltose complex versus ferrous sulfate in pregnant women with iron-deficiency anemia: a multicenter, randomized, controlled study. Breymann, C; Frer, C; Macagno, E; Monterrosa, B; Ortiz, R; Romero, JD; Toblli, JE, 2011) | 0.37 |
| " The median prevalence of adverse drug reactions for IPM (2." | ( Safety and efficacy of intravenous iron polymaltose, iron sucrose and ferric carboxymaltose in pregnancy: A systematic review. Grivell, RM; Grzeskowiak, LE; Mol, BW; Qassim, A, 2018) | 0.48 |
| " Basic demographics, infusion indication, starting hemoglobin and ferritin, vital signs and medical details of patients who had an adverse reaction were recorded." | ( Safety profile of iron polymaltose infusions. Lee, AYS; Leung, SHP, 2019) | 0.51 |
| "Iron polymaltose has a low rate of adverse drug reactions; yet, serious side-effects such as hypotension may occur." | ( Safety profile of iron polymaltose infusions. Lee, AYS; Leung, SHP, 2019) | 0.51 |
| " However, oral iron supplements are toxic to the gastrointestinal mucosa and intolerance is common, resulting in poor compliance and failure of treatment." | ( Comparison of efficacy & safety of iron polymaltose complex & ferrous ascorbate with ferrous sulphate in pregnant women with iron-deficiency anaemia. Chavan, S; Rana, P; Tekur, U; Tripathi, R, 2021) | 0.62 |
| " They were then followed up for 90 days to observe for improvement in the haemoglobin levels and other haematological parameters or any adverse drug reaction." | ( Comparison of efficacy & safety of iron polymaltose complex & ferrous ascorbate with ferrous sulphate in pregnant women with iron-deficiency anaemia. Chavan, S; Rana, P; Tekur, U; Tripathi, R, 2021) | 0.62 |
| " The overall adverse effect profiles were also comparable among the study groups except epigastric pain which was more commonly reported in the FS group." | ( Comparison of efficacy & safety of iron polymaltose complex & ferrous ascorbate with ferrous sulphate in pregnant women with iron-deficiency anaemia. Chavan, S; Rana, P; Tekur, U; Tripathi, R, 2021) | 0.62 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Similar pharmacokinetic differences of these two iron preparations could also be found in clinical trials, which means that different serum iron increase results in an equal utilization ratio for both preparations." | ( Pharmacokinetics of iron salts and ferric hydroxide-carbohydrate complexes. Geisser, P; Müller, A, 1987) | 0.27 |
| " IPC had no pharmacokinetic effect on the rate of absorption of tetracycline." | ( Effect of an oral iron(III)-hydroxide polymaltose complex on tetracycline pharmacokinetics in patients with iron deficiency anemia. Geisser, P; Jacobs, YL; Potgieter, MA; Pretorius, SG; Venter, C; Venter, JL, 2007) | 0.34 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " It was concluded that bioavailability is comparable for therapeutic doses of ferrous sulphate and iron polymaltose in iron-deficient subjects." | ( Absorption of iron polymaltose and ferrous sulphate in rats and humans. A comparative study. Gregory, MC; Jacobs, P; Wormald, LA, 1979) | 0.26 |
| "The comparative bioavailability from matching quantities of iron in the form of ferrous ascorbate or ferric polymaltose was defined in rats." | ( Bioavailability and the mechanisms of intestinal absorption of iron from ferrous ascorbate and ferric polymaltose in experimental animals. Jacobs, P; Johnson, G, 1990) | 0.28 |
| " In subjects with depleted iron stores the relative bioavailability was decreased from 100 to 14% for the HP-Fe." | ( Intestinal absorption of 59Fe from neutron-activated commercial oral iron(III)-citrate and iron(III)-hydroxide-polymaltose complexes in man. Heinrich, HC, 1987) | 0.27 |
| " The comparable bioavailability was maintained when demand was increased by iron depletion or erythroid stimulation and depressed by expansion of body stores or impaired erythropoiesis." | ( Equivalent bioavailability of iron from ferrous salts and a ferric polymaltose complex. Clinical and experimental studies. Jacobs, P, 1987) | 0.27 |
| "The bioavailability of iron on Fe(III)-hydroxide-polymaltose complex was compared intraindividually with that of Fe (II)-ascorbate (iron absorption) and a Fe (II)-sulphate quick release preparation (haemoglobin regeneration test)." | ( Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations. Kaltwasser, JP; Niechzial, M; Werner, E, 1987) | 0.27 |
| "The iron (III)-hydroxide-dextrin complexes in two commercial preparations were compared with alleged reproduction which have been prepared for bioavailability studies published recently." | ( Chemical characterization of iron (III)-hydroxide-dextrin complexes. A comparative study of commercial preparations with alleged reproductions used in the examination of bioavailability. Erni, I; Oswald, N; Rich, HW; Schneider, W, 1984) | 0.27 |
| " No significant difference in bioavailability or iron utilization was found between the two iron preparations." | ( Iron pharmacokinetics after administration of ferric-hydroxide-polymaltose complex in rats. Geisser, P; Müller, A, 1984) | 0.27 |
| " In the first study, bioavailability of iron from ferrous sulfate and the complex was defined at physiologic doses of 5 mg (Group 1: n = 14) and therapeutic doses of 50 mg (Group 2: n = 13)." | ( Oral iron therapy in human subjects, comparative absorption between ferrous salts and iron polymaltose. Jacobs, P; Johnson, G; Wood, L, 1984) | 0.27 |
| "The bioavailability or iron from iron(III)hydroxide polymaltose complex (ferric polymaltose, Fe-PM) was studied in human volunteers with normal or depleted iron stores as well as in patients with iron deficiency anemia." | ( Bioavailability of iron from oral ferric polymaltose in humans. Fischer, R; Gabbe, EE; Heinrich, HC; Nielsen, P, 1994) | 0.29 |
| " The bioavailability of ferric compounds has been questioned and accordingly their therapeutic role remains controversial." | ( Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron-deficient blood donors. Coghlan, P; Fransman, D; Jacobs, P, 1993) | 0.29 |
| " Although many authors and clinical practice guidelines recommend primary oral iron supplementation in ESA-treated PD patients, numerous studies have clearly demonstrated that, because of a combination of poor bioavailability of oral iron, gastrointestinal intolerance, and noncompliance, oral iron supplementation is insufficient for maintaining a positive iron balance in these patients over time." | ( Intravenous versus oral iron supplementation in peritoneal dialysis patients. Johnson, DW, 2007) | 0.34 |
| "Simple iron salts, such as iron sulphate, often interact with food and other medications reducing bioavailability and tolerability." | ( Interactions between iron(III)-hydroxide polymaltose complex and commonly used medications / laboratory studies in rats. Canclini, C; Funk, F; Geisser, P, 2007) | 0.34 |
| " IPC had no pharmacokinetic effect on the rate of absorption of tetracycline." | ( Effect of an oral iron(III)-hydroxide polymaltose complex on tetracycline pharmacokinetics in patients with iron deficiency anemia. Geisser, P; Jacobs, YL; Potgieter, MA; Pretorius, SG; Venter, C; Venter, JL, 2007) | 0.34 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "In both experimental animals and human subjects iron absorption over a wide dosage range was quantitatively equivalent from ferrous salts and a ferric polymaltose complex under basal conditions." | ( Equivalent bioavailability of iron from ferrous salts and a ferric polymaltose complex. Clinical and experimental studies. Jacobs, P, 1987) | 0.27 |
| " Adequate intravenous iron supplementation allows reduction of epoetin dosage by approximately 40%." | ( Safety aspects of parenteral iron in patients with end-stage renal disease. Hörl, WH; Sunder-Plassmann, G, 1997) | 0.3 |
| " The available iron pool was maintained with 100 mg iron every 2 weeks or 1 month depending on serum ferritin and transferrin saturation levels, the rHuEPO dosage titrated depending on hematocrit (Hct) levels." | ( Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. Chang, CC; Chang, CH; Chiang, SS, 2002) | 0.31 |
| " Besides, the iPTH levels did not interfere with the rHuEPO dosage reduction and Hct increment in our patients." | ( Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. Chang, CC; Chang, CH; Chiang, SS, 2002) | 0.31 |
| "In any context of iron supplementation in the prenatal prophylaxis or therapeutic dosage range, a large amount will remain unabsorbed and pass through the intestinal tract into the colonic digesta possibly causing increased oxidation." | ( Equivalent effects on fecal reactive oxygen species generation with oral supplementation of three iron compounds: ferrous sulfate, sodium iron EDTA and iron polymaltose. Arriaga, C; Orozco, MN; Schümann, K; Solomons, NW, 2012) | 0.38 |
| "Oral iron supplementation with ferrous sulfate (FeSO₄) at dosage levels suggested by the international guidelines poses a safety hazard to young children with malaria." | ( Oral administration of ferrous sulfate, but not of iron polymaltose or sodium iron ethylenediaminetetraacetic acid (NaFeEDTA), results in a substantial increase of non-transferrin-bound iron in healthy iron-adequate men. Marx, J; Orozco, M; Romero-Abal, ME; Schümann, K; Solomons, NW; Weiss, G, 2012) | 0.38 |
| " Diagnosis of anaemia and/or iron deficiency, infusion dosage characteristics and haematological parameters were collected from paper-based case notes and electronic records." | ( Approaches for optimising intravenous iron dosing in pregnancy: a retrospective cohort study. Grivell, RM; Grzeskowiak, LE; Jeffries, B; Qassim, A, 2017) | 0.46 |
| "Optimal treatment outcomes in pregnant women requiring intravenous iron may be reached by dosing according to adjusted pre-pregnancy bodyweight rather than ideal bodyweight." | ( Approaches for optimising intravenous iron dosing in pregnancy: a retrospective cohort study. Grivell, RM; Grzeskowiak, LE; Jeffries, B; Qassim, A, 2017) | 0.46 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 17 (12.78) | 18.7374 |
| 1990's | 19 (14.29) | 18.2507 |
| 2000's | 41 (30.83) | 29.6817 |
| 2010's | 47 (35.34) | 24.3611 |
| 2020's | 9 (6.77) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 42 (30.66%) | 5.53% |
| Reviews | 10 (7.30%) | 6.00% |
| Case Studies | 11 (8.03%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 74 (54.01%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| the Effectiveness of Lactoferrin in Treatment of Iron Deficiency Anemia in Children With Chronic Tonsillitis [NCT03748043] | Phase 4 | 100 participants (Anticipated) | Interventional | 2019-02-21 | Recruiting | ||
| The Role of Intravenous Iron to Prevent Anemia in Women With Breast Cancer Receiving (Neo)Adjuvant Chemotherapy [NCT01168505] | Phase 2 | 100 participants (Anticipated) | Interventional | 2010-05-31 | Recruiting | ||
| Rationale and Design of Ferric Polymaltose Hydroxide and Iron Sucrose Evaluation on Performance and Oxydative Stress in Patient With Iron deficIency and Stable Heart Failure Study [NCT04225728] | Phase 4 | 45 participants (Actual) | Interventional | 2017-12-01 | Completed | ||
| Iron Supplementation for Acute Anemia After Postbariatric Abdominoplasty: a Randomized Controlled Trial [NCT01857011] | Phase 3 | 56 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| Effektivität Der in Der Schwangerschaftsvorsorge routinemässig Angewandten Eisenprophylaxe [NCT02487719] | Phase 4 | 150 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||